Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Abstract

These data show that the PPARgamma ligand/carboplatin combination is a new therapy worthy of clinical investigation in lung cancers, including those cancers that show primary resistance to platinum therapy or acquired resistance to targeted therapy.